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Summary: A time-resolved fluoroimmuno assay of the IgM-rheumatoid factor is described. Aggregated rabbit
IgG was coated to microtitre plates to serve as the target protein. F(ab')2-fragments from antibodies, raised
in rabbits against human IgM, were labelled with Eu3+ and used in the assay to mark the bound IgM-
rheumatoid factor. The labelling procedure is easy to perform, and there is no need for special equipment.
The shelf life of the label at —20 °C is at least one year. The lower detection limit of the assay is 1.3 χ
ΙΟ3 IU/1. The range over which the IgM-rheumatoid factor can be measured at a within-run precision of
< 5% without varying the dilution (working range) is 5 — 1200 χ l O3 IU/1. Linearity in serum dilutions is
good. There is good correlation with existing methods for the assay of IgM-rheumatoid factor. This correlation
is better with an assay using rabbit IgG as the target than with one using human IgG. Comparison of methods
shows that standardization, despite the use of the WHO Reference Preparation as the first calibrator, remains
problematic. The 95th percentile in normal bloodbank donors is 8 χ ΙΟ3 IU/1. The costs for the reagents were
about 0.5 Dutch florin (ca 0.30 US-$) per well. In conclusion, the method described here is analytically at
least comparable with other methods, in precision, linearity, working range etc. Finally, it is easy to perform.
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OU . A . . , . ,_, , . - nosorbent assay (Ehsa) (4).ican Rheumatism Association (1). For a long period
of time, the techniques for the estimation of rheu- However, within-run coefficients of variation (CV's)
matoid factor remained relatively unchanged. The of > 10%, which in our opinion are analytically
Waaler-Rose test or latex-fixation test, which meas- unacceptable, are not uncommon in these assays, es-
ures serial dilutions of patient serum, is still widely pecially at high and low concentrations. Furthermore,
used. Inter-laboratory variability was reduced by the the limited working range often makes it necessary to
introduction of the International Unit, defined by the assay the patient sera in different dilutions. Our ex-
International Reference Preparation (IRP) of the perience with other assays showed that the technique
World Health Organization (WHO) (2). However, as of the time-resolved fluoroimmuno assay, as used in
a consequence of the generally used semi-quantitative the Delfiatm system (Pharmacia, Turku, Finland),
methods, values for rheumatoid factor were still re- could possibly overcome these disadvantages. Since
ported in steps differing by a factor of two. This leads there is no immediate prospect of a commercial kit
to artificially high inter-laboratory variation. The de- appearing on the market, we decided to design our
velopment of immunoassays introduced the possibil- own assay, including the labelling of a tracer with
ity of fully quantitative determinations of the rheu- europium. We describe here this time-resolved fluo-
matoid factor, and the opportunity to further reduce roimmuno assay for the IgM-type rheumatoid factor,
the inter-laboratory variation. Moreover, these assays It is easy to perform and cost effective.
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Materials and Methods
Reagents
Phosphate-buffered saline: 9 g/1 NaCl, 10 mmol/1 phosphate,
pH = 7.4.
Coating buffer: phosphate-buffered saline containing 5 g/1 bo-
vine serum albumin, fatty acid-free (Sigma, St. Louis MO,
USA) and 7.7 mmol/1 NaN3.
Assay buffer: phosphate-buffered saline containing 5 g/1 bovine
serum albumin, fatty acid-free (Sigma) and 200 μΐ/ΐ Tween-20tm
(Merck, Darmstadt, Germany).
Washing buffer: 9 g/1 NaCl, 20 mmol/1 TRIS-HC1, 7.7 mmol/1
NaN3 and 200 μΐ/ΐ Tween-20tm, pH = 7.8.
Coating solution: 25 mg rabbit IgG (Nordic, Tilburg, The
Netherlands) was dissolved in 2 ml demineralized water. To
accomplish aggregation of the IgG, this solution was incubated
20 min at 63 °C. Subsequently, it was diluted in phosphate-
buffered saline to give a stock solution of 1.25 g/1, portions of
which were stored at — 20 °C. The coating was performed at a
final concentration of aggregated rabbit IgG of 25 mg/1 in
phosphate-buffered saline.
Solid phase: high-binding, flat-bottomed polystyrene microtitre
plates (Greiner, Alphen a/d Rijn, The Netherlands) were coated
by incubating the wells overnight at room temperature with
100 μΐ of coating solution. Subsequently, the excess was re-
moved. Some of the plates were freshly used. To assess the
choice of storage conditions, the remaining plates, at this state
of preparation, were divided in two lots. The first lot was stored
at 4 °C in a humidified atmosphere for 1 -12 weeks, the second
at -20 °C for 1 -12 weeks. Before use, a second coating with
bovine serum albumin was performed on the fresh and the
stored plates by incubating the wells with 200 μΐ coating buffer
for 2 hours at room temperature.
Labelled antibody: F(ab')2-fragments from antibodies raised in
rabbits against human IgM (Dako A/S, Glostrup, Denmark)
were labelled with Eu3+, using the labelling reagent (Pharmacia,
Turku, Finland), containing N-l-(p-isothiocyanatophenyl)
diethylene-triamine-N1,N2,N3-tetraacetate. The labelling pro-
cedure and the method for estimating the labelling index are
described elsewere (5). In short: a fifty-fold molar excess of the
labelling reagent was incubated overnight at room temperature
with the F(ab')2-fragments. The labelled fraction was isolated
by gel filtration (PD-10 column). A solution of 0.80 g/1 labelled
antibody with a labelling index of 5.5 mol europium per mol
antibody was obtained. This preparation was used in the ex-
periments described, at a final concentration of 1.6 mg/1 in
assay buffer. The labelled antibody was stored at -20 °C. The
shelf life under these conditions is at least one year.
Enhancement solution (Pharmacia, Turku, Finland): 6.8 mmol/1
potassium hydrogen phthalate, 100 mmol/1 acetic acid, 50
μπιοΐ/ΐ tri-rt-octylphosphine oxide, 15 μηιοΐ/ΐ 2-naphthoyltri-
fluoro-acetone and 1 g/1 Triton X-100.
Calibrators
For the calibration we used the Dutch National Reference
Preparation (DNRP) (Foundation Reference Laboratory of
Rheumatoid Serology (RELARES), Amsterdam, The Nether-
lands), which is calibrated against the International Reference
Preparation (IRP) of Rheumatoid Arthritis Serum (World
Health Organization WHO), and contains 200 IU per ampoule
IgM-rheumatoid factor (6). This preparation was dissolved in
distilled water and diluted in assay buffer to obtain a set of
calibrating solutions covering the concentration range 5 to 1200
χ 103 IU/1. As a check, we determined the IgM-rheumatoid
factor concentration of the Dutch National Reference Prepa-
ration against the International Reference Preparation of the
WHO by the time-resolved fluoroimmuno assay. One ampoule
of the WHO International Reference Preparation was donated
by RELARES. It was reconstituted in 1 ml distilled water. This
solution contains 100 χ ΙΟ3 IU/1 by definition.
Samples
For the estimation of the between-run precision, five patient
sera were selected with low, intermediate and high concentra-
tions of IgM-type rheumatoid factor. Aliquots were stored at
— 20 °C. For the comparison between the different IgM-rheu-
matoid factor assays, sera were selected from patients suspected
of suffering from rheumatoid arthritis. These sera were stored
at -20 °C before the assay.
Methods
The assay was performed at room temperature and consisted
of:
1) 2 h incubation of the coated microtitre well with 100 μΐ of
the calibration solutions, samples (diluted 1 : 500 in assay
buffer), or blank (assay buffer), in duplicate;
2) six washing steps with washing buffer;
3) incubation with the labelled antibody with slow shaking for
2h;
4) six washing steps with washing buffer;
5) addition of 100 μΐ of the enhancement solution;
6) measurement of the time resolved fluorescence with the
Arcus Fluorometer (Pharmacia, Turku, Finland).
The efficiency of the binding of IgM-rheumatoid factor to the
solid phase was tested as follows: after step 1 of the assay
procedure, the fluid from the well was pipetted into a second,
fresh well and further assayed. This enables both the direct
measurement of the bound IgM-rheumatoid factor in the first
well and the residual IgM-rheumatoid factor in the second.
From these results the percentage bound to the first well can
be calculated.
For the method comparison the rheumatoid factor was also
measured by Elisa (Malakit IgM-rheumatoid factor IgM anti
rabbit IgG, Biolab, Wavre, Belgium) and by rate nephelometry
with aggregated human IgG as the antigen (RHF^-kit on an
ARRAY-analyzer, Beckman, Brea CA, USA), according to the
instructions of the manufacturers. Results were calculated based
on the standards delivered with the kits. The statistical analysis
was performed according to Passing & Bablok (7).
Results
The mean labelling index (N = 4) was 5.5 mol/mol
(range 5 — 6 mol/mol).
The efficiency of the binding of the IgM-rheumatoid
factor to the solid phase was 93 + 5% (mean ± SD)
in the sera tested (N = 7). The efficiency was not
concentration-dependent in the range tested (26 —
1233 χ 103 IU/1). We found no significant deviation
in the IgM-rheumatoid factor concentration of the
Dutch National Reference Preparation from the 200
χ 103 IU/1 established by the manufacturer, when we
measured it against the WHO International Reference
Preparation under the conditions of the assay de-
scribed.
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Assay characteristics
The lower detection limit was estimated by replicate
analysis (N = 10) of the assay buffer. It was defined
as the IgM-rheumatoid factor corresponding to the
mean + 3 SD response of the assay buffer. The limit
found was 1.3 χ ΙΟ3 IU/1.
The within-run precision was estimated by measuring
9 patient sera with different IgM-rheumatoid factor
in replicate (N = 8). The precision profile is shown
in figure 1. The IgM-rheumatoid factor can be meas-
ured at an acceptable precision of < 5%, without
varying the dilution factor, in the range 5 — 1200
χ 103 IU/1.
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Fig. 1. Calibration curve and precision profile.
Calibration curve (circles): fluorescence at varying IgM-
rheumatoid factor concentrations. Precision profile (tri-
angles): IgM-rheumatoid factor concentration of nine
patient sera were measured in replicate (N = 8). The
coefficients of variation were plotted against the mean
concentrations (triangles).
Between-run precision was compared for plates that
were precoated batchwise with IgG, then stored, and
for freshly prepared plates; the results are shown in
table 1. The between-run precision was estimated by
measuring five patient sera in duplicate in eight runs
for the three storage conditions of the microtitre
plates.
Tab. 1. Between-run CV's under different conditions of micro-
titre plate storage. For each condition, the IgM-rheu-
matoid factor concentrations of the 5 patient sera were
measured in 8 runs. For further experimental details
see Materials and Methods.
Mean con-
centration
(103 IU/1)
9
13
76
245
404
Coefficient of variation (%)
fresh made
19.7
15.5
26.0
9.4
20.2
stored 4 °C
13.0
4.3
9.9
4.8
10.8
stored
14.4
4.5
16.7
8.2
12.6
-20°C
Linearity was tested in two ways. A serum sample
with a high IgM-rheumatoid factor was diluted seri-
ally with a) the assay buffer, b) a serum with a low
IgM-rheumatoid factor, and assayed as a sample. The
results are shown in figure 2.
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Fig. 2. Linearity.
A serum sample with a high IgM-rheumatoid factor
concentration was diluted serially with
a) assay buffer (circles),
b) a serum with a low IgM-rheumatoid factor concen-
tration (triangles).
The measured IgM-rheumatoid factor concentration
was plotted against the fraction of the high IgM-rheu-
matoid factor serum.
In normal healthy blood bank donors (N = 33)
8 χ 103 IU/1 was established as the 95th percentile of
the IgM-rheumatoid factor concentration.
Comparison with other methods
The correlation between the results of the different
quantitative methods tested, is shown in figures 3a
and 3b.
The regression between the time-resolved fluorescence
(x) and the Elisa (y) was: y = 1.65 χ - 19.42. The
slope shows a significant deviation from 1. The y-
intercept is not significantly different from zero
(p < 0.05). The coefficient of correlation was 0.95.
The regression between the time-resolved fluorescence
(x) and the rate nephelometry (z) was: ζ = 0.98 χ
+ 4.09. Slope and z-intercept do not deviate signifi-
cantly from 1 and zero, respectively (p < 0.05). The
coefficient of correlation was 0.88.
Costs
The costs for reagents were only about HF1 0.50 (ca.
0.30 US-$) per well.
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Fig. 3. Assay comparison.
Figure 3a shows the comparison of the results obtained by nephelometry and the time-resolved fluoroimmuno assay. Sera
of 33 patients were measured in both assays.
y = 0.98 χ + 4.09
Figure 3b shows the comparison of the Elisa and the time-resolved fluoroimmuno assay. The results of 27 patient sera,
obtained in both assays were plotted.
y = 1.65x - 19.42
Regression analysis was performed according to Passing & Bablok (7).
Discussion
Many combinations of components are possible for
an assay of the IgM-rheumatoid factor. With respect
to the target antigen, there is much discussion in the
literature about the use of IgG of human or rabbit
origin. Human IgG possibly better reflects the in vivo
situation. On the other hand, rabbit IgG, the antigen
in the classic Waaler-Rose test, is more specific for
rheumatoid arthritis (8). For this reason we prefer the
rabbit IgG. To increase the avidity of the IgM-rheu-
matoid factor for the antigen, we used the aggregated
form of the IgG (9).
The decision to use only the F(ab')2-fragment of an
antibody against human IgM as the tracer is dictated
by the fact that the rheumatoid factors, irrespective
of the immunoglobin class to which they belong, must
not bind to a Fc fragment of this antibody; this would
give false results.
On the basis of the results in table 1, we choose to
store the batchwise precoated microtitre plates at 4 °C
in a humidified atmosphere, for routine use. Although
a between-run precision up to 13% in IgM-rheuma-
toid factor assays is not uncommon (3, 10, 11), we
think that the high ratio between between-run and
within-run precision suggests that a decrease of the
between-run CV can be achieved. Therefore, we in-
vestigated the effect of performing the second coating
with bovine serum albumin, batchwise, before the
storage, instead of afterwards. This even worsened
the CV's (results not shown). Further studies on the
preservation and storage of the plates, to improve the
between-run precision, are under investigation.
In the comparison between the described assay and
nephelometry, it can be seen that in many patients
the rheumatoid factors are different. This is not sur-
prising because the two methods differ markedly in
the detection technique, the antigen used etc. The
correlation with the Elisa is better. Here, a comparable
antigen, namely from rabbit, is used and both assays
are IgM specific. The slope of the regression line of
1.65, significantly deviating from 1, can be ascribed
to the standardization, in spite of the fact that both
assays are calibrated on the same International Ref-
erence Preparation from the World Health Organi-
zation. A comparable conclusion has been published
by Jaspers et al. (10). It can be explained by the fact
that the IgM-rheumatoid factor in the International
Reference Preparation is, as a consequence of its
polyclonal source, a mixture of different IgM mole-
cules, each with its own characteristics, such as av-
idity, specificity etc. The same holds for the Dutch
National Reference Preparation, and of course for
the patient sera. Standardizing one mixture against
another is of course not allowed theoretically, but it
is not always avoidable at the present state of the art.
We agree with the suggestion of H0ier-Madsen et al.
(11) that, at present, the only way to obtain compar-
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able results between laboratories seems to be the use
of the same method. A disadvantage of this approach,
however, is that it does not stimulate research and
marketing to introduce better methods.
We were not able to estimate the 95th percentile in a
group of control subjects as defined by the American
Rheumatism Association (1). We found a value of
8 χ 103 IU/1 in healthy blood bank donors. This is
comparable with the finding of others (12). The value
given here can only be considered as an indication of
a reference value, because the group tested is not a
matched control group. It does demonstrate, however,
that normal people have detectable IgM-rheumatoid
factor concentrations.
In our laboratory, we use the generally accepted
20 χ 103 IU/1 as the cut-off limit for pathology. Re-
sults between 8 and 20 χ 10~3 IU/1 can be considered
as suspect. Perhaps these patients have an enhanced
chance of subsequently developing rheumatoid ar-
thritis. Because of its technical advantages, such as
low background, high precision, large working range
and long shelf life of the label, the technique of the
time-resolved fluoroimmuno assay has established its
position in the field of binding analysis. The IgM-
rheumatoid factor assay described here has these same
advantages. The one-site preparation of europium
labels is not yet practised widely in routine clinical
laboratories. It should be stressed, that the procedure
is very simple and therefore deserves more attention.
On site labelling is possible in any normally equipped
laboratory. The reagent costs of the assay are low,
mainly because of the long shelf-life and low con-
sumption of the labelled antibody.
In conclusion, the method described here is analyti-
cally at least comparable with other methods, in de-
tection limit, precision, linearity, working range etc.
It is cheap and easily to perform in practice.
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